One of the most important therapeutic advance in lung cancer management had been the identification of specific driver mutations and the development of small molecular tyrosine kinase inhibitors (TKIs).3 More recently, checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and its ligand (PD‐L1) have been developed, which offer exciting immune‐based therapeutic options. Here, PDCD1 is linked to lung cancer.